Multiple in vitro and in vivo studies have demonstrated that activation of the PI3K/AKT/mTOR pathway induces resistance to endocrine treatment32, 33 and the mTOR inhibitor everolimus showed clinical efficacy with exemestane in HR+ ABC by targeting this pathway.34 Here, AKT1 is linked to aneurysmal bone cyst.